Cell-proliferation imaging for monitoring response to CDK4/6 inhibition combined with endocrine-therapy in breast cancer: Comparison of [18F]FLT and [18F]ISO-1 PET/CT

Azadeh Elmi, Mehran Makvandi, Chi-Chang Weng, Catherine Hou, Amy S. Clark, Robert H Mach, David A Mankoff
2019 Clinical Cancer Research  
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in combination with endocrine-therapy have emerged as an important regimen of care for estrogen receptor (ER)-positive metastatic breast cancer, although identifying predictive biomarkers remains a challenge. We assessed the ability of two PET-proliferation tracers, [18F]FLT and [18F]ISO-1, for evaluating response to CDK4/6-inhibitor (palbociclib) and ER-antagonist (fulvestrant).
doi:10.1158/1078-0432.ccr-18-2769 pmid:30692100 pmcid:PMC9788667 fatcat:n6zf6vpxpzbc5mxm7yqdyy7s3q